A cohort of 115 MS patients along with 44 age- and sex-matched healthy controls underwent brain and cervical cord 3T MRI with pulse sequences. Of the MS cohort, 57 patients had relapsing-remitting MS, 12 primary progressive MS, and 46 secondary progressive MS. Lesions, atrophy, and microstructural damage were assessed. A complete neurological assessment with Expanded Disability Status Scale (EDSS) rating was performed as well.
Five clusters of MS patients were identified: âearlyâ, âintermediate-cordâ, âintermediate-corticalâ, âintermediate-late-lesionâ, and âlateâ. Early patients showed similar MRI metrics as healthy controls (except lesions), low EDSS, and short disease duration. Compared with early patients, intermediate patients were characterised by altered MRI metrics, higher EDSS, and longer disease duration (P<0.01). Intermediate-cord patients stood out by high cord T2-lesion volume (LV), except versus late patients (P<0.001). The intermediate-cortical group had relatively low cortical thickness (P<0.001), except versus intermediate-late-lesion and late patients. Intermediate-late-lesion patients had a longer disease duration, a higher brain T2-LV, and deep grey matter (GM) atrophy, except compared with late patients (P<0.01). Of all groups, the late patients had the worst corticospinal-tract diffusion-tensor metrics and cord/brain atrophy (P<0.01); they also had higher EDSS and disease duration than the intermediate-cord and the intermediate-cortical patients (P<0.01).
The authors suggest that intermediate-cord patients could be divided into 2 groups that differ in cord GM atrophy and cortical thickness (P<0.01), the impaired group including mostly progressive phenotypes and higher EDSS. They believe the intermediate-cord group is best suited to study neuroprotective and regenerative strategies.
- Bonacchi R, et al. Abstract O2029, EAN 2020.
Posted on
Previous Article
« Serum NfL predicts long-term clinical outcomes in MS Next Article
Imaging to evaluate remyelination and neuroprotection »
« Serum NfL predicts long-term clinical outcomes in MS Next Article
Imaging to evaluate remyelination and neuroprotection »
Table of Contents: EAN 2020
Featured articles
Alzheimer's Disease and Other Dementias
Non-Alzheimerâs disease pathophysiology in the elderly
Novel genetic association with resistance to ERC tau deposition
Diastolic dysfunction novel risk factor for cognitive impairment
Epilepsy
Avoidable epilepsy-related mortality remains high
How genetic testing can contribute to epilepsy management
Cenobamate effective in focal epilepsy
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome
Prevalence of autoantibodies in epilepsy almost 10%
Parkinson's Disease
White matter matters in Parkinsonâs disease
Sleep disorders mark PD progression
Directional DBS superior to omnidirectional DBS
Stroke
Benefits of statins to prevent stroke outweigh risks
Extubation after thrombectomy: the sooner, the better
Thrombus location and length predictors of early neurological deterioration
Endovascular treatment in large vessel occlusion stroke patients treated with OAC
Early edoxaban may be safe after cardioembolic stroke
Headache and Pain
Small fibre pathology as biomarker for fibromyalgia
Migraine as a cyclical functional disorder
Reassuring real-world safety profile of 3 CGRP inhibitors
Long-term cardiovascular safety of erenumab
Real-world data for erenumab in Germany
Eptinezumab in chronic migraine and medication-overuse headache
Fremanezumab tolerability in cardiovascular patients with migraine
Effects of galcanezumab on health-related quality of life
Multiple Sclerosis
Imaging to evaluate remyelination and neuroprotection
Serum NfL predicts long-term clinical outcomes in MS
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
High NEDA rates after 2 years of ocrelizumab
Switching from natalizumab to moderate- versus high-efficacy DMT
Results of compounds in late stages of development
Alemtuzumab efficacy and safety data of over 9 years
Fampridine treatment results in routine clinical practice
Air pollution is a possible risk factor for MS
Neuromyelitis Optica Spectrum Disorder
Genetic association studies in NMOSD needed
Eculizumab in NMOSD: the PREVENT study
Long-term safety of satralizumab consistent with double-blind periods
Neuromuscular Disorders
Biomarkers predicting motor function in SMA
Sustained benefits of avalglucosidase alfa in late-onset Pompe disease
Efficacy and safety of rituximab in refractory MG corroborated
Related Articles
September 9, 2020
Long-term safety of ND0612 in idiopathic PD
September 10, 2020
Alemtuzumab efficacy and safety data of over 9 years
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com